Asia’s First Private Driving Club “THE MAGARIGAWA CLUB” Scheduled to Open Late 2022 in Tokyo Area
13.8.2020 13:00:00 EEST | Business Wire | Press release
Cornes & Company Ltd. started construction on THE MAGARIGAWA CLUB this past spring in Minamiboso in Chiba Prefecture. In creating the club, Cornes envisions a truly unique driving club, road course, and destination that will offer experiences unattainable at other racing circuits. Located 60minutes from the Tokyo metro area, Tokyo International Airport, and Narita International Airport, the exclusive driving club allows members to enjoy an unparalleled driving experience and spectacular views of Mt. Fuji and Tokyo Bay. In addition to its distinctive 3.5-kilometer driving course, THE MAGARIGAWA CLUB offers recreational options for everyone—not just car enthusiasts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200813005038/en/
Driving Course (Graphic: Business Wire)
The first round of applications for membership are sold out.
Concept
There are a few legendary racetracks in the world today. These spots gain iconic status, becoming destinations for piston-heads. Aiming to put THE MAGARIGAWA CLUB on the map, too, Cornes wants to turn it into an iconic destination by creating an exceptional, world-class driving club.
The name and logomark of the club are based on the kanji “<<<(magarigawa)”. Cornes hopes that MAGARIGAWA’s members will be able to fully immerse themselves in the beautiful natural landscape allowing them to become one with nature and have experiences that they won’t get anywhere else in the world.
Road course
The driving course was designed by the world renown team at Tilke Engineers & Architects. It is the first course in Japan that the team has designed from scratch and features a maximum ascent of 20%, maximum descent of 16%, and an 800-meter long straight, making it a track like no other. It is challenging but also designed for safety, letting drivers focus on the driving experience. Members can drive their automobiles on the course, store them on site, and get maintenance checks before and after driving. They can take one-on-one lessons with professional instructors and explore the potential of their favorite cars in a safe manner. The climate-controlled pit building can accommodate up to 36 vehicles and there are other services and facilities that help ensure a satisfying driving experience.
Other Major Facilities
Clubhouse
The design of the clubhouse combines elements from both traditional Japanese and contemporary architecture. Inside the clubhouse members will find a bar, restaurant, family lounge, gymnasium, 25m swimming pool, spa facilities, and natural hot spring baths. Outside, there is a playground, dog run, and hiking trails.
Owner’s paddocks and long-term garage
Each owner’s paddock provides private indoor parking for up to 4 automobiles and features a spacious floorplan that includes a dining area, living room, and terrace. There is also a long-term car storage facility which is highly secure and climate controlled. On-site mechanics keep members’ vehicles in top condition for driving.
“Magarigawa will be home for car lovers. A sanctuary where members will be able to enjoy and share their passion with friends and family.” said Kenzo Watari, CEO, Cornes Group.
“It will be the answer to the perennial question – where do you drive an 800 horsepower supercar?”
“The extremely hilly topography offers an astonishing basis for the track and makes the layout absolutely unique in the world.” said Dr. Carsten Tilke, Managing Director, Tilke Engineers & Architects. “Although we have designed and realized over 80 racetracks worldwide including 19 Formula One circuits, this project was very special to us and we are proud to be part of it.
Drivers will enjoy mid-speed, technical sections as well as two high-speed straights of the 3.5km track, which incorporates highest safety and environmental standards. It will be ideal for all kinds of driver skills. As a car enthusiast and racing driver myself, I can’t wait to drive my first laps at this amazing unique track.”
For more information, visit www.magarigawa.com.
Overview
Name: THE MAGARIGAWA CLUB
Location: Minamiboso, Chiba Prefecture, Japan
Date of opening: Scheduled for late 2022
Total site area: 1,000,000sq.m
Track specs: 3.5km in length, max. ascent: 20%, max. descent: 16％, 800m long straight, 22 corners, elevation change of 250m
Convenient: 60minutes from Tokyo & Haneda Airport
About Cornes & Company Ltd.
Established in 1861, Cornes & Co., Ltd. specializes in the import and sale of electronic components, systems equipment, industrial machinery, laboratory equipment and scientific instruments, apparels, fragrances, kitchenware, and nautical charts and publications and has expanded its business into a wide range of areas including non-life insurance and marine insurance survey. Its subsidiary companies Cornes Motors Ltd. and C.P.S. Ltd, are authorized distributors of Rolls-Royce, Bentley, Ferrari, Lamborghini, and Porsche automobiles. Cornes Motors is the leading ultra luxury automotive dealership in Japan.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005038/en/
Contact information
Contact for inquiries regarding this matter
Platinum Co., Ltd.
Person in charge: Saori Miyazaki
Email: magarigawa_pr@vectorinc.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom